BG Medicine Release: Automated VIDAS® Galectin-3 Assay Validated In Published Clinical Research Study

WALTHAM, Mass., Jan. 28, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, welcomed today the publication of results of a clinical research study that demonstrate and validate the analytical and clinical performance of the automated VIDAS® Galectin-3 assay that was developed by bioMérieux SA, a world leader in the field of in vitro diagnostics and one of BG Medicine's automation partners.

Help employers find you! Check out all the jobs and post your resume.